首页> 外文期刊>Scandinavian journal of rheumatology >Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trals of six weeks duration.
【24h】

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trals of six weeks duration.

机译:骨关节炎患者低剂量罗非考昔与1000毫克萘普生的比较。持续时间为六周的两次随机治疗的结果。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To compare the efficacy and safety of rofecoxib 12.5 mg once daily to naproxen 500 mg twice daily in patients > or = 40 years of age with knee or hip osteoarthritis (OA). METHOD: Two identical 6-week, randomized, double-blind studies were conducted (1 in Africa, Australia, Europe, Canada, Mexico, & South America; 1 in Asia). Primary endpoints were pain walking on a flat surface, patient global assessment of response to therapy, and investigator global assessment of disease status. RESULTS: Overall, 944 patients participated. For all efficacy endpoints, treatment effects for rofecoxib and naproxen were comparable and seen at the first measures of efficacy. Both compounds were generally well-tolerated, with an improved gastrointestinal safety profile for rofecoxib versus naproxen. CONCLUSIONS In these studies, rofecoxib 12.5 mg once daily (the lowest indicated dose) and naproxen 500 mg twice daily showed similar treatment effects in OA patients. Rofecoxib and naproxen were generally well tolerated.
机译:目的:比较年龄≥40岁的膝或髋关节骨关节炎(OA)患者中每天12.5 mg的罗非考昔与每天500 mg的萘普生的疗效和安全性。方法:进行了两个相同的为期6周的随机双盲研究(非洲,澳大利亚,欧洲,加拿大,墨西哥和南美为1个,亚洲为1个)。主要终点是在平坦表面上行走的疼痛,对治疗反应的患者总体评估以及研究者对疾病状况的总体评估。结果:总共有944例患者参加。对于所有功效终点,罗非考昔和萘普生的治疗效果均具有可比性,并在疗效的第一个指标上可见。两种化合物通常都具有良好的耐受性,罗非昔布和萘普生对胃肠道的安全性均有改善。结论在这些研究中,罗非考昔每天12.5 mg(指示的最低剂量)和萘普生500 mg每天两次,在OA患者中显示出相似的治疗效果。罗非昔布和萘普生一般耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号